Skeletal Dysplasia Account Manager - Oklahoma City/Tulsa

8–10 years in pharmaceutical or biotech; 4+ years in rare disease, genetic disease, or skeletal dysplasia required.

Achondroplasia or pediatric rare disease experience highly preferred.

Product/indication launch experience:

Proven record of accomplishment launching products into competitive or new markets, including creating demand through disease-state and stakeholder education.

Success analyzing complex accounts, building strategy, and driving implementation to deliver measurable impact.

Demonstrated curiosity and adaptability with AI-powered tools and technologies.

The Skeletal Dysplasia Account Manager is a high-impact, community-focused role central to BridgeBio’s commercial success.

This individual will drive the launch of Infigratinib—a first-in-class therapy for achondroplasia—bring deep clinical acumen, urgency, and a passion for partnering with providers and families.

Develop and execute a dynamic territory business plan targeting geneticists, pediatric endocrinologists, orthopedic specialists, pediatricians, and multi-disciplinary skeletal dysplasia clinic teams to meet and exceed sales goals.

Demonstrate deep expertise in Infigratinib, achondroplasia, and the broader skeletal dysplasia landscape; engage HCPs in clinically relevant, compliant discussions.

Use sales and target data to identify growth opportunities and address territory challenges proactively.

Anticipates potential business challenges, adjusts priorities as needed, demonstrates flexibility, and develops solutions to address challenges.